Therapeutic Response
dMMR status confers therapeutic sensitivity to Pembrolizumab in patients with Gastrointestinal Stromal Tumor.
Statements
| Source and description |
|---|
dMMR status confers therapeutic sensitivity to Pembrolizumab in patients with Gastrointestinal Stromal Tumor.
| Source and description |
|---|